Arcturus Therapeutics Holdings Inc.
ARCT
$6.65
$0.060.91%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -58.84% | -43.24% | -22.70% | -26.22% | -7.68% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -58.84% | -43.24% | -22.70% | -26.22% | -7.68% |
| Cost of Revenue | -23.96% | -49.58% | -34.87% | 19.55% | -91.40% |
| Gross Profit | -62.96% | 85.49% | 64.58% | -264.51% | 727.89% |
| SG&A Expenses | -21.68% | -16.06% | -23.81% | -1.02% | -0.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -35.77% | -43.77% | -32.47% | 14.32% | -18.69% |
| Operating Income | -53.79% | 45.02% | 44.67% | -82.76% | 44.41% |
| Income Before Tax | -88.88% | 47.16% | 46.78% | -162.20% | 53.55% |
| Income Tax Expenses | -- | 102.67% | -- | -101.53% | -124.30% |
| Earnings from Continuing Operations | -94.81% | 46.68% | 47.51% | -156.30% | 57.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -94.81% | 46.68% | 47.51% | -156.30% | 57.45% |
| EBIT | -53.79% | 45.02% | 44.67% | -82.76% | 44.41% |
| EBITDA | -60.30% | 46.40% | 45.69% | -86.60% | 46.85% |
| EPS Basic | -93.88% | 46.99% | 47.95% | -152.80% | 58.21% |
| Normalized Basic EPS | -88.02% | 47.48% | 47.24% | -158.64% | 54.40% |
| EPS Diluted | -93.88% | 46.99% | 47.95% | -151.18% | 58.21% |
| Normalized Diluted EPS | -88.02% | 47.48% | 47.24% | -158.64% | 54.40% |
| Average Basic Shares Outstanding | 0.47% | 0.60% | 0.85% | 1.40% | 1.84% |
| Average Diluted Shares Outstanding | 0.47% | 0.60% | 0.85% | 1.40% | 1.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |